Precise theranostic nanomedicines for inhibiting vulnerable atherosclerotic plaque progression through regulation of vascular smooth muscle cell phenotype switching

Coronary heart disease is a prevalent and fatal killer caused by vulnerable atherosclerotic plaques (VASPs). However, the precise detection and treatment of VASPs remains a difficult challenge. Here, we present the development of noninvasive human serum albumin (HSA)-based theranostic nanomedicines...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Theranostics
Autors principals: Ma, Sai, Motevalli, Seyed Mohammad, Chen, Jiangwei, Xu, Meng-Qi, Wang, Yabin, Feng, Jing, Qiu, Ya, Han, Dong, Fan, Miaomiao, Ding, Meiling, Fan, Li, Guo, Weisheng, Liang, Xing-Jie, Cao, Feng
Format: Artigo
Idioma:Inglês
Publicat: Ivyspring International Publisher 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6037040/
https://ncbi.nlm.nih.gov/pubmed/30026877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.24364
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars